Follow on

There’s Now a Way to Diagnose IBS With a Simple Blood Test.- The IBS Smart Test

IBS-smart measures the levels of two validated IBS biomarkers, anti-CdtB and anti-vinculin. These biomarkers are elevated in a majority of IBS patients with diarrheal symptoms and can diagnose diarrhea-predominant or mixed-type IBS (IBS-D or IBS-M). These biomarkers are not commonly elevated in patients with constipation-predominant IBS (IBS-C). Only a licensed physician can order ibs-smart and diagnose IBS. 

Is IBS Smart Test Right For You?

Have you been experiencing the following symptoms once or more a week for at least four weeks? 

  • Diarrhea or alternating diarrhea and constipation

  • Stomach pain 

  • Bloating

AdobeStock_288330109.jpeg

If you have been experiencing these symptoms, IBS-smart could help you begin the right treatment quickly and prevent years of potentially unnecessary procedures like colonoscopies.

How do you test for IBS?
  • IBS has traditionally been diagnosed using multiple tests to exclude the possibility of other diseases. If no other health issues are found, a diagnosis of IBS is made.

  • Scientists have since discovered validated biomarkers for IBS that can be measured with a blood test. These biomarkers are effective in diagnosing the majority of IBS-D and IBS-M cases.

  • IBS Smart Test is the only licensed, patented blood test that measures these biomarkers to diagnose IBS.

    ibs-smart-Right-Clean.png

     

 If your IBS Smart test results are positive:
  • You know with certainty that you have IBS. The organic biomarkers tested by ibs-check test have a positive predictive value of IBS that is 96%-100%. 
  • You know the cause, which can help personalize treatment.
  • If the measured biomarkers are elevated, your IBS developed from gastroenteritis (food poisoning). This means your gut microbiome has been disrupted, indicating that treatments that target the gut microbiome could be effective for you. 
Getting the IBS Smart test could help avoid years of additional testing and costs.
 
IBS Smart Test® – The First Clinically Validated Blood Test for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M).

 

IBS and SIBO-Is there a connection?

It is now known, based on extensive human and animal research, that acute gastroenteritis leads to IBS. In animal studies, infection with campylobacter jejuni (C. jejuni) caused small intestinal bacterial overgrowth. C. jejuni infection also leads to the production of the anti-CdtB and anti-vinculin antibodies detected by IBS Smart Test.

In the same animal studies, antibody levels were related to the number of infections the animals experienced. However, irrespective of the number of infections with C. jejuni, bacterial overgrowth was more closely related to the antibodies than the number of infections.

Here’s how food poisoning leads to IBS.  (Watch Dr Hagmeyer’s Video below)

Is IBS Smart test for people with diarrhea and mixed IBS?

IBS Smart  has been validated in diagnosing irritable bowel syndrome associated with diarrhea and mixed symptoms. Published studies have determined the cost savings—both direct and indirect—to the patient and healthcare system from receiving a faster diagnosis.

Does IBS Smart suggest what treatment is best for me?

A positive IBS Smart can confirm that you have IBS-S or IBS-M and that your disease is an organic condition based on the presence of validated biomarkers. IBS Smart  does not offer insight into which treatment is best for your irritable bowel syndrome patient. If this test is positive, Dr Hagmeyer may recommend additional testing.

IBS Smart  is performed in a CLIA-certified laboratory and results can provide you and your health care provider with actionable clinical data and a better understanding of your health.

The IBS- Smart Test  and consult with Dr Hagmeyer Includes:

  1. Test Requisition Form;
  2. Easy-to-follow Instructions for Use;
  3. Sterile Collection and Return Materials; and
  4. Pre-Paid Return Shipping Label
  5. 30 minute Consult with Dr Hagmeyer

Consult with Dr Hagmeyer

  • Every test ordered through the DrHagmeyer.com website includes the following
  • The ordering of the test kit on your behalf
  • Interpretation of testing
  • 30 minute consult with to discuss lab testing findings and recommendation on what to do next.
  • Return shipping to lab
 

 

IBS Check Test and Consult For IBS-D and IBS-M 5About IBS Smart Test

IBS Smart Test is a proprietary blood test for IBS based on the scientific findings of a 2500+ patient clinical trial which showed that anti-vinculin and anti-CdtB are effective biomarkers for the diagnosis of diarrhea-predominant or mixed-symptom IBS. Irritable Bowel Syndrome (IBS) is the most common functional gastrointestinal syndrome in the U.S. It is estimated that up to 45 million people, or 10-15% of the American population, suffer from IBS.

FAQ

Q.  What is IBS Smart Test?

IBS Smart Test is a proprietary blood test for IBS based on the scientific findings of a 2500+ patient clinical trial which showed that anti-vinculin and anti-CdtB are effective biomarkers for the diagnosis of diarrhea-predominant or mixed-symptom IBS.  Click here to read published clinical data validating IBS Smart for diagnosing IBS-D and IBS-M.

Q.  How quickly can I receive results from your lab?

When the sample arrives at our laboratory, it will be analyzed within 24-48 hours.  When our office has been notified of your test Results and Dr Hagmeyer has reviewed them, you will be contacted to schedule a 30 minute consult with Dr Hagmeyer or one of his associates.

Published Clinical Data Validating IBS Smart Test for Diagnosing IBS-D and IBS-M

“Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects” Mark Pimentel, Walter Morales, Ali Rezaie, et al. PLoS One. 2015; 10:e0126438.

“Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.” Rezaie A, Park SC, Morales W et al. Dig Dis Sci. 2017 Jun; 62(6):1480-1485.

“Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.” Schmulson M, Balbuena R, Corona de Law C. Rev Gastroenterol Mex. 2016 Oct – Dec;81(4):236-239.

“The Utility of Measuring Anti-Cytolethal Distending Toxin B and Anti-Vinculin Antibodies in a Tertiary Care Motility Practice: A Free-Range Experience.” Pourmorady J, Rezaie A, Pimentel M, et al. Gastroenterology. 2016;4 (Suppl1): S-230.

**Result data should be interpreted with the help of a qualified health care provider and all clinical decisions should consider other symptoms and health factors in disease diagnosis and management.